文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌术后放疗后预测≥2级放射性肺炎的临床与剂量学因素

Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-12

该研究回顾性分析了199例接受术后放疗(联合或不联合化疗)的非小细胞肺癌患者的资料,旨在找出预测≥2级放射性肺炎的临床与剂量学因素并建立风险模型。结果发现仅肺V10>30%和V20>20%可预测≥2级放射性肺炎,据此划分的高、中、低危组发生率分别为33%、23%和6%(P<.0001)。

要点

  • 仅肺V10>30%和V20>20%预测≥2级放射性肺炎,患者因素、手术类型、化疗及放疗相关因素均无关联。
  • 高危组(V10>30%且V20>20%)33%、中危组23%、低危组6%发生≥2级放射性肺炎(P<.0001)。
  • 肺叶切除亚组中高、中、低危组发生率分别为34%、23%和9%(P=.001)。

核心结论

  • 肺剂量体积参数V10和V20可预测接受术后放疗的非小细胞肺癌患者≥2级放射性肺炎的风险。

研究设计与样本

  • 回顾性分析199例接受术后放疗(联合或不联合化疗)的非小细胞肺癌患者的放疗、影像和临床数据。

主要发现

  • 37例(19%)发生≥2级放射性肺炎;患者相关因素、手术类型、化疗及放疗相关因素与≥2级放射性肺炎无关;仅肺V10>30%和V20>20%可预测≥2级放射性肺炎。
  • 风险分组:高危组(V10>30%且V20>20%)72例中24例(33%);中危组(V10>30%且V20≤20%或V10≤30%且V20>20%)26例中6例(23%);低危组(V10≤30%且V20≤20%)101例中6例(6%),P<.0001。
  • 肺叶切除亚组中,高危组59例中20例(34%)、中危组22例中5例(23%)、低危组70例中6例(9%)发生≥2级放射性肺炎,P=.001。

关键数值与推荐

  • 肺V10>30%且V20>20%定义为高危组,≥2级放射性肺炎发生率为33%(24/72)。
  • 肺V10>30%且V20≤20%或V10≤30%且V20>20%定义为中危组,≥2级放射性肺炎发生率为23%(6/26)。
  • 肺V10≤30%且V20≤20%定义为低危组,≥2级放射性肺炎发生率为6%(6/101)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify clinical and dosimetric factors that would predict grade ≥2 radiation pneumonitis (RP) for patients undergoing postoperative radiation therapy (PORT) for non-small cell lung cancer (NSCLC); and to use the factors identified to generate a predictive model to quantify risk of RP in such patients. METHODS AND MATERIALS: We retrospectively reviewed radiation therapy, radiographic, and clinical data from 199 patients who had received PORT, with or without chemotherapy, for NSCLC. Potential associations between dosimetric and clinical factors and RP were evaluated in univariate and multivariate Cox regression hazard models and competing risk analysis. Kaplan-Meier analysis was used to estimate overall survival and the cumulative incidence of RP, and receiver operating characteristic curve analysis to identify cutpoints for variables found to influence RP risk. The endpoint was grade ≥2 RP (symptomatic, requiring steroids or limiting instrumental activities of daily living). RESULTS: Thirty-seven patients (19%) developed grade ≥2 RP. Patient-related factors, type of surgery or chemotherapy, and radiation therapy-related factors were not associated with grade ≥2 RP; only lung V10 > 30% and lung V20 > 20% predicted grade ≥2 RP. Risk groupings were as follows: high risk, V10 > 30% and V20 > 20% (24 of 72 patients, 33%); intermediate risk, V10 > 30% and V20 ≤ 20% or V10 ≤ 30% and V20 > 20% (6 of 26 patients, 23%); and low risk, V10 ≤ 30% and V20 ≤ 20% (6 of 101 patients, 6%) (P < .0001). In a subgroup analysis of patients who had had lobectomy, corresponding incidences of RP were as follows: high risk, 20 of 59 (34%); intermediate risk, 5 of 22 (23%); and low risk, 6 of 70 (9%) (P = .001). CONCLUSIONS: The lung dose-volume variables V10 and V20 predicted risk of grade ≥2 RP among patients who underwent PORT for NSCLC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Boonyawan K, Gomez DR, Komaki R, et al. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976504. doi:10.1016/j.ijrobp.2018.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。